Skip to main content

Advertisement

Table 3 Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  Intent to treat analysis
  KRASwild-type KRASmutant All
  No % No % No %
Enrolled patients 31 100 28 100 59 100
Evaluable patients 30 97 27 96 57 97
Objective response 27 90 (95% CI 79 to 100) 18 67 (95% CI 49 to 85) 45 79 (95% CI 68 to 100)
Partial response 23 77 17 63 40 70
Complete response 4 13 1 4 4 7
Stable disease 2 7 5 18.5 7 12
Progressive disease 1 3 4 15 5 9
Median PFS, months 14   11   12  
Range 1+-69+   1+-60+   1+-69+  
Progression events 25 81 20 71 45 76
Median OS, months 38   20   28  
Range 1+-69+   1+-60+   1+-69+  
Deaths 17 55 17 61 34 58
Liver metastasectomies 11   7   18  
No/overall patients 11/31 35 7/28 25 18/59 31
No/patients with liver metastases 11/19 58 7/20 35 18/39 46
No/patients with L-L metastases 10/12 83 7/13 54 17/25 68
Pathologic complete responses - - 2 28.5 2 11
  1. L-L = liver limited; OS = overall survival; PFS = progression-free survival.